AngioDynamics has been granted a patent for a system and method for ablating tissue cells using High-Frequency Irreversible Electroporation (HFIRE). The system includes a single-pole electrode probe inserted into the treatment region and an external surface electrode placed outside the patient’s body. A control device delivers electric energy to the treatment region through HFIRE pulses. The method involves placing the probe and surface electrode at different locations on the organ’s surface and generating electrical pulses to induce ablation zones. GlobalData’s report on AngioDynamics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights AngioDynamics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AngioDynamics, Target mapping ablation catheters was a key innovation area identified from patents. AngioDynamics's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for high-frequency irreversible electroporation method

Source: United States Patent and Trademark Office (USPTO). Credit: AngioDynamics Inc

A recently granted patent (Publication Number: US11723710B2) describes a method for ablating cells in a treatment site of a patient using electrical pulses. The method involves placing a probe with a probe electrode into the treatment site and a surface electrode on the surface of an organ. A generator is activated to generate a first set of electrical pulses between the probe electrode and the surface electrode, creating an initial ablation zone and inducing a first electrical pull zone to increase the size of the ablation zone. This process is repeated at different locations on the organ using a second set of electrical pulses to induce a second electrical pull zone.

The method described in the patent claims is specifically designed to ablate cells in a treatment site without causing thermal damage to surrounding tissue or inducing muscle contractions in the patient. The electrical pulses used are bi-phasic and have specific pulse widths and burst widths. The generator is also capable of generating electrical pulses in a predetermined pattern to maintain the temperature of the treatment site below 70 degrees Celsius.

The patent also mentions the use of a single-pole tine style electrode probe and the monitoring of impedance in the initial ablation zone. Additionally, the method can involve the use of deployable tine electrodes for more effective ablation.

Overall, this patented method provides a non-thermal and non-muscle contraction-based approach to ablating cells in a treatment site. By utilizing specific electrical pulse parameters and patterns, the method aims to achieve effective cell ablation while minimizing damage to surrounding tissue. The patent's claims cover various aspects of the method, including electrode configurations, pulse characteristics, and the use of deployable tine electrodes.

To know more about GlobalData’s detailed insights on AngioDynamics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.